Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Individuals with type 2 diabetes typically experience an impaired incretin effect, though GLP-1 secretion itself may be normal, slightly reduced, or context-dependent
May support evaluation Common Eligibility Factors BMI of 30 or greater BMI of 27 or greater with a related health condition Prior lifestyle efforts without durable results Ability to attend monitoring and report symptoms Willingness to support nutrition, movement, and maintenance Needs more review Reasons to Avoid, Delay, or Modify Treatment Pregnancy, planned pregnancy, or breastfeeding Personal or family history of medullary thyroid carcinoma or MEN2 for Wegovy/Zepbound Severe gastroparesis or significant gastrointestinal disease Active or unstable eating disorder Prior serious allergy to the medicine Inability to maintain fluid or nutrition Medication interactions or uncontrolled illness These medicines are not intended for cosmetic weight loss The goal is treatment of obesity or clinically significant overweight-related risknot rapid loss of a few pounds for an event
MartnIRodrguezAAlaAMartnez-BlancoMLozano-OjalvoDCrdobaJJ
The move comes after an increase in reports of acute pancreatitis to the Medicines and Healthcare products Regulatory Agencys (MHRA) Yellow Card scheme, which monitors any adverse reactions to medications and medical devices in the UK
US$ 26.39
US$ 24.95
US$ 28.19
